A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the analgesic efficacy, safety and tolerability of
multiple doses of JNJ-42160443 when administered as a single, subcutaneous injection every 28
days to patients with diabetic painful neuropathy (a disease condition in diabetic patients
that affects all peripheral nerves including pain fibers, motor neurons and the autonomic
nervous system).
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.